HDAC3 and Huntington disease: However, given the above-mentioned literature implicating HDAC3 specifically in HD, in this study we further explored the effects of an HDAC3-selective inhibitor, RGFP966 ((E)-N-(2-amino-4-fluorophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide) [20], in HD transgenic mice to assess its effects on motor behavior and neuroprotection.